Rigel Pharmaceuticals (RIGL) Invested Capital (2016 - 2025)
Historic Invested Capital for Rigel Pharmaceuticals (RIGL) over the last 17 years, with Q3 2025 value amounting to $147.4 million.
- Rigel Pharmaceuticals' Invested Capital rose 110690.08% to $147.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $147.4 million, marking a year-over-year increase of 110690.08%. This contributed to the annual value of $10.6 million for FY2024, which is 14931.12% up from last year.
- Latest data reveals that Rigel Pharmaceuticals reported Invested Capital of $147.4 million as of Q3 2025, which was up 110690.08% from $104.3 million recorded in Q2 2025.
- Over the past 5 years, Rigel Pharmaceuticals' Invested Capital peaked at $147.4 million during Q3 2025, and registered a low of -$31.8 million during Q3 2023.
- For the 5-year period, Rigel Pharmaceuticals' Invested Capital averaged around $17.1 million, with its median value being -$3.7 million (2022).
- Its Invested Capital has fluctuated over the past 5 years, first plummeted by 66461.79% in 2023, then soared by 110690.08% in 2025.
- Over the past 5 years, Rigel Pharmaceuticals' Invested Capital (Quarter) stood at $30.4 million in 2021, then tumbled by 144.83% to -$13.6 million in 2022, then plummeted by 57.28% to -$21.4 million in 2023, then soared by 149.31% to $10.6 million in 2024, then surged by 1295.55% to $147.4 million in 2025.
- Its Invested Capital was $147.4 million in Q3 2025, compared to $104.3 million in Q2 2025 and $33.4 million in Q1 2025.